Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outset Medical (OM) Current Deferred Revenue (2019 - 2025)

Outset Medical (OM) has disclosed Current Deferred Revenue for 7 consecutive years, with $13.8 million as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue rose 8.17% to $13.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.8 million through Dec 2025, up 8.17% year-over-year, with the annual reading at $13.8 million for FY2025, 8.17% up from the prior year.
  • Current Deferred Revenue for Q4 2025 was $13.8 million at Outset Medical, down from $14.9 million in the prior quarter.
  • The five-year high for Current Deferred Revenue was $14.9 million in Q3 2025, with the low at $3.5 million in Q1 2021.
  • Average Current Deferred Revenue over 5 years is $10.0 million, with a median of $10.8 million recorded in 2023.
  • The sharpest move saw Current Deferred Revenue soared 98.06% in 2021, then grew 2.73% in 2025.
  • Over 5 years, Current Deferred Revenue stood at $6.3 million in 2021, then soared by 36.62% to $8.7 million in 2022, then surged by 35.38% to $11.7 million in 2023, then grew by 8.75% to $12.8 million in 2024, then rose by 8.17% to $13.8 million in 2025.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $13.8 million, $14.9 million, and $14.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.